Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

The use of cerebrospinal … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials

Artikel i vetenskaplig tidskrift
Författare Bob Olsson
J. M. Schott
Kaj Blennow
Henrik Zetterberg
Publicerad i Expert Review of Neurotherapeutics
Volym 17
Nummer/häfte 8
Sidor 767-775
ISSN 1473-7175
Publiceringsår 2017
Publicerad vid Institutionen för neurovetenskap och fysiologi
Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 767-775
Språk en
Länkar doi.org/10.1080/14737175.2017.13413...
Ämnesord CSF, biomarkers, clinical trial, Alzheimer's disease, neurodegeneration, creutzfeldt-jakob-disease, csf neurofilament proteins, gamma-secretase, inhibition, mild cognitive impairment, amyloid-beta, total tau, frontotemporal dementia, national institute, double-blind, phospho-tau, Neurosciences & Neurology, Pharmacology & Pharmacy, khann g, 1984, neurology, v34, p939
Ämneskategorier Klinisk medicin

Sammanfattning

Introduction: All recent phase 3 trials of potentially disease-modifying therapies for Alzheimer's disease (AD) have so far failed. Potential reasons include enrolling subjects whose disease is too advanced or who do not have AD pathology, or simply incorrect drug targets. The goal of disease-modifying AD trials is to halt the progress of neuronal damage and death and this can be assessed in vivo using cerebrospinal fluid (CSF) biomarkers.Areas covered: The authors conducted a literature search of the use of CSF biomarkers in disease-modifying AD clinical trials using PubMed. The authors show that CSF biomarkers have only sparsely been used as outcome measures, and where they have, only in small subsets of patients. No clinical trials have yet showed any substantial effects on CSF biomarkers of neurodegeneration.Expert commentary: In future trials, the authors advocate that CSF biomarkers be used more extensively to optimize the chance of detecting positive drug effects. This includes the identification of potential AD patients - already in the early prodromal stage - for inclusion, for stratification, as readout i.e. proximity markers for changes in axonal/neurodegeneration between treatment and placebo groups - this also enables proof of principle verification in the discovery/dose finding phase, and for monitoring of side effects.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?